Clinical Features of Friedreich’s Ataxia. Mitochondrial Function as a Therapeutic Target
Differential and neuropathological diagnosis of encephalitis
it
Prof. Luca Massacesi
Parkinson's, hopes for ongoing studies on new molecules
it
Prof. Fabrizio Stocchi
SIN Congress 2024: centrality of brain health
it
Prof. Giancarlo Comi
Tardive dyskinesia: new drugs, useful complement to antipsychotic therapy
it
Prof. Angelo Antonini
Ofatumumab in MS: Real-world data confirms efficacy in early treatment
it
Prof. Massimiliano Mirabella
Epilepsy: increasingly patient-oriented therapeutic approach
it
Prof. Angelo Labate
ALS: tofersen, early access for patients with SOD1 mutation
it
Prof. Valeria Sansone
Reimbursement for atogepant in the prevention of episodic migraine
it
Prof. Cristina Tassorelli
Clinical Features of Friedreich’s Ataxia. Mitochondrial Function as a Therapeutic Target
it
Dr. Francesco Saccà
MS: kesimpta and siponimod in early therapy with high efficacy
it
Prof. Massimiliano Calabrese
Encephalitis: advances in diagnosis and appropriateness of treatment
it
Duchenne DM: givinostat to slow muscle degeneration, waiting for new drugs
it
Prof. Valeria Sansone